Overview

Denosumab Compared to Zoledronic Acid in the Treatment of Bone Disease in Patients With Multiple Myeloma

Status:
Completed
Trial end date:
2019-03-29
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if denosumab is non-inferior to zoledronic acid in the treatment of bone disease from multiple myeloma.
Phase:
Phase 3
Details
Lead Sponsor:
Amgen
Collaborators:
Daiichi Sankyo Inc.
Daiichi Sankyo, Inc.
Treatments:
Bone Density Conservation Agents
Denosumab
Diphosphonates
Zoledronic Acid